HUP0003679A2 - PKC inhibitorok alkalmazása kardiovaszkuláris megbetegedések kezelésére szolgáló gyógyászati készítmények előállítására - Google Patents
PKC inhibitorok alkalmazása kardiovaszkuláris megbetegedések kezelésére szolgáló gyógyászati készítmények előállításáraInfo
- Publication number
- HUP0003679A2 HUP0003679A2 HU0003679A HUP0003679A HUP0003679A2 HU P0003679 A2 HUP0003679 A2 HU P0003679A2 HU 0003679 A HU0003679 A HU 0003679A HU P0003679 A HUP0003679 A HU P0003679A HU P0003679 A2 HUP0003679 A2 HU P0003679A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- treatment
- cardiovascular diseases
- alkylene
- alkyl group
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002947 alkylene group Chemical group 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000002619 bicyclic group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 abstract 1
- 206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 206010027525 Microalbuminuria Diseases 0.000 abstract 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 abstract 1
- 125000004450 alkenylene group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 230000006931 brain damage Effects 0.000 abstract 1
- 231100000874 brain damage Toxicity 0.000 abstract 1
- 208000029028 brain injury Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 125000004674 methylcarbonyl group Chemical group CC(=O)* 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000003881 protein kinase C inhibitor Substances 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 125000005156 substituted alkylene group Chemical group 0.000 abstract 1
- 210000003556 vascular endothelial cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/17—Unsaturated ethers containing halogen
- C07C43/174—Unsaturated ethers containing halogen containing six-membered aromatic rings
- C07C43/1745—Unsaturated ethers containing halogen containing six-membered aromatic rings having more than one ether bound
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C43/00—Ethers; Compounds having groups, groups or groups
- C07C43/02—Ethers
- C07C43/03—Ethers having all ether-oxygen atoms bound to acyclic carbon atoms
- C07C43/14—Unsaturated ethers
- C07C43/178—Unsaturated ethers containing hydroxy or O-metal groups
- C07C43/1785—Unsaturated ethers containing hydroxy or O-metal groups having more than one ether bound
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
A találmány tárgya az (I) általános képletű protein kináz C inhibitoralkalmazása emlősök ér endotheliális sejtdiszfunkciójának kezelésérealkalmas gyógyászati készítmény előállítására - a képletben W jelentése -O-, -S-, -SO-, -SO2-, -CO-, alkilén-, helyettesítettalkilén-, alkenilén-, aril-, aril-(CH2)mO-, heterogyűrűs, heterogyűrű-(CH2)mO-, kondenzált biciklusos csoport, kondenzált biciklusos -(CH2)mO-, -NR3-, -NOR3-, -CONH- vagy -NHCO- csoport; X és Y jelentése egymástól függetlenül alkiléncsoport, helyettesítettalkiléncsoport vagy X, Y és W együtt -(CH2)n-AA- általános képletűcsoportot alkot; az R1 helyettesítők jelentése hidrogénatom vagy legfeljebb 4 adottesetben jelen lévő helyettesítő, amelyek jelentése egymástólfüggetlenül halogénatom, alkilcsoport, hidroxilcsoport, alkoxicsoport,halogénezett alkilcsoport, nitrocsoport, -NR4R5 vagy -NHCO-alkil-csoport; R2 jelentése hidrogénatom, CH3CO-, -NH2 vagy hidroxilcsoport.Különösen alkalmasak a fenti vegyületek emlősök kardiovaszkulárismegbetegedéseinek kezelésére vagy megelőzésére, mikroalbuminuriájának,központi ischémiás agykárosodásának, restenózisának, érelmeszesedésesállapotainak és pangásos szívelégtelenségének kezelésére szolgálógyógyászati készítmények előállítására. Ó
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/662,623 US5723456A (en) | 1993-12-07 | 1996-06-13 | Therapeutic treatment for cardiovascular diseases |
PCT/US1997/009661 WO1997047298A1 (en) | 1996-06-13 | 1997-06-12 | Therapeutic treatment for cardiovascular diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0003679A2 true HUP0003679A2 (hu) | 2001-04-28 |
HUP0003679A3 HUP0003679A3 (en) | 2002-09-30 |
Family
ID=24658463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0003679A HUP0003679A3 (en) | 1996-06-13 | 1997-06-12 | Use of pkc inhibitors for the preparation of pharmaceutical compositions treating cardiovascular diseases |
Country Status (20)
Country | Link |
---|---|
US (1) | US5723456A (hu) |
EP (1) | EP0954308B1 (hu) |
JP (1) | JP2000512293A (hu) |
KR (1) | KR20000016625A (hu) |
AT (1) | ATE315933T1 (hu) |
AU (1) | AU725582B2 (hu) |
BR (1) | BR9709727A (hu) |
CA (1) | CA2257693A1 (hu) |
CZ (1) | CZ406798A3 (hu) |
DE (1) | DE69735134T2 (hu) |
EA (1) | EA005035B1 (hu) |
ES (1) | ES2255106T3 (hu) |
HU (1) | HUP0003679A3 (hu) |
IL (1) | IL127524A0 (hu) |
NO (1) | NO318193B1 (hu) |
NZ (1) | NZ333341A (hu) |
PL (1) | PL189253B1 (hu) |
UA (1) | UA49025C2 (hu) |
WO (1) | WO1997047298A1 (hu) |
YU (1) | YU57398A (hu) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6147109A (en) * | 1997-10-14 | 2000-11-14 | The General Hospital Corporation | Upregulation of Type III endothelial cell Nitric Oxide Synthase by HMG-CoA reductase inhibitors |
US6180597B1 (en) * | 1998-03-19 | 2001-01-30 | Brigham And Women's Hospital, Inc. | Upregulation of Type III endothelial cell nitric oxide synthase by rho GTPase function inhibitors |
US6127401A (en) | 1998-06-05 | 2000-10-03 | Cephalon, Inc. | Bridged indenopyrrolocarbazoles |
US6423751B1 (en) | 1998-07-14 | 2002-07-23 | The Brigham And Women's Hospital, Inc. | Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization |
US6303646B1 (en) | 1999-08-09 | 2001-10-16 | Zhimin Lu | Cancer treatment with Gö 6976 |
CN1950502B (zh) * | 2003-09-19 | 2011-07-27 | 儿童医院医学中心 | 心肌收缩性和心力衰竭倾向的调节 |
GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
DE102004019413A1 (de) * | 2004-04-19 | 2005-11-24 | Phenos Gmbh | Hemmung der Proteinkinase C epsilon zur Behandlung von Krankheiten |
CN1274303C (zh) * | 2004-07-09 | 2006-09-13 | 吕志民 | 一种化合物及其衍生物在制备防治癌症药物中的应用 |
GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
US7741290B2 (en) * | 2006-06-01 | 2010-06-22 | The Board of Trustee of The Leland Stanford Juinior University | Method of preventing progression of hypertension-induced heart failure with PKC peptides |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0699311B2 (ja) * | 1986-11-06 | 1994-12-07 | 旭化成工業株式会社 | 抗血管レン縮剤および血管弛緩剤 |
US4785085A (en) * | 1986-11-21 | 1988-11-15 | Bristol-Myers Company | Rebeccamycin analogs |
US4808613A (en) * | 1986-11-21 | 1989-02-28 | Bristol-Myers Company | Rebeccamycin derivative containing pharmaceutical composition |
EP0303697B1 (en) * | 1987-03-09 | 1997-10-01 | Kyowa Hakko Kogyo Co., Ltd. | Derivatives of physiologically active substance k-252 |
JPH07113027B2 (ja) * | 1987-12-24 | 1995-12-06 | 協和醗酵工業株式会社 | K−252誘導体 |
US5438050A (en) * | 1988-02-06 | 1995-08-01 | Godecke Aktiengesellschaft | Indolocarbazole derivatives, processes for their preparation and compositions containing them |
DE3803620A1 (de) * | 1988-02-06 | 1989-08-17 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel |
SK75289A3 (en) * | 1988-02-10 | 1998-05-06 | Hoffmann La Roche | Substituted pyrroles, their use for producing a drug, and the drug on their base |
MC2096A1 (fr) * | 1989-02-23 | 1991-02-15 | Hoffmann La Roche | Pyrroles substitues |
DE3914764A1 (de) * | 1989-05-05 | 1990-11-08 | Goedecke Ag | Maleinimid-derivate und deren verwendung als arzneimittel |
US5380746A (en) * | 1989-05-05 | 1995-01-10 | Goedecke Aktiengesellschaft | Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
IL94274A0 (en) * | 1989-05-05 | 1991-03-10 | Goedecke Ag | Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same |
DE3924538A1 (de) * | 1989-07-25 | 1991-01-31 | Goedecke Ag | Indolocarbazol und dessen verwendung |
DE3942296A1 (de) * | 1989-12-21 | 1991-06-27 | Goedecke Ag | Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung |
DE4005969A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
DE4005970A1 (de) * | 1990-02-26 | 1991-08-29 | Boehringer Mannheim Gmbh | Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten |
CA2046801C (en) * | 1990-08-07 | 2002-02-26 | Peter D. Davis | Substituted pyrroles |
US5292747A (en) * | 1990-08-07 | 1994-03-08 | Hoffman-La Roche Inc. | Substituted pyrroles |
JPH04187687A (ja) * | 1990-11-21 | 1992-07-06 | Fuji Photo Film Co Ltd | フルオラン化合物の製造方法 |
HUT70187A (en) * | 1991-04-11 | 1995-09-28 | Schering Corp | Process for preparing oxadiazepine derivatives condensed with indole and pharmaceutical compositions of anti-tumor and anti-psoriatic activity containing said compounds |
GB9123396D0 (en) * | 1991-11-04 | 1991-12-18 | Hoffmann La Roche | A process for the manufacture of substituted maleimides |
US5461146A (en) * | 1992-07-24 | 1995-10-24 | Cephalon, Inc. | Selected protein kinase inhibitors for the treatment of neurological disorders |
WO1994007895A1 (en) * | 1992-09-25 | 1994-04-14 | Schering Corporation | Diindolo compounds and pharmaceutical compositions containing them |
DE4243321A1 (de) * | 1992-12-21 | 1994-06-23 | Goedecke Ag | Aminosäurederivate von Heterocyclen als PKC-Inhibitoren |
AU678435B2 (en) * | 1993-05-10 | 1997-05-29 | F. Hoffmann-La Roche Ag | Substituted pyrroles |
KR100340159B1 (ko) * | 1993-12-07 | 2002-11-23 | 일라이 릴리 앤드 캄파니 | 단백질키나제c억제제 |
US5624949A (en) * | 1993-12-07 | 1997-04-29 | Eli Lilly And Company | Protein kinase C inhibitors |
US5559228A (en) * | 1995-03-30 | 1996-09-24 | Eli Lilly And Company | Synthesis of bisindolylmaleimides |
UA54427C2 (uk) * | 1996-05-01 | 2003-03-17 | Елі Ліллі Енд Компані | Спосіб лікування очних захворювань, які пов'язані з фактором васкулярного ендотеліального росту |
-
1996
- 1996-06-13 US US08/662,623 patent/US5723456A/en not_active Expired - Fee Related
-
1997
- 1997-06-12 EA EA199900025A patent/EA005035B1/ru not_active IP Right Cessation
- 1997-06-12 PL PL97330604A patent/PL189253B1/pl not_active IP Right Cessation
- 1997-06-12 DE DE69735134T patent/DE69735134T2/de not_active Expired - Fee Related
- 1997-06-12 CA CA002257693A patent/CA2257693A1/en not_active Abandoned
- 1997-06-12 UA UA99010154A patent/UA49025C2/uk unknown
- 1997-06-12 BR BR9709727A patent/BR9709727A/pt not_active Application Discontinuation
- 1997-06-12 HU HU0003679A patent/HUP0003679A3/hu unknown
- 1997-06-12 NZ NZ333341A patent/NZ333341A/xx unknown
- 1997-06-12 EP EP97931034A patent/EP0954308B1/en not_active Expired - Lifetime
- 1997-06-12 YU YU57398A patent/YU57398A/sh unknown
- 1997-06-12 IL IL12752497A patent/IL127524A0/xx unknown
- 1997-06-12 AT AT97931034T patent/ATE315933T1/de not_active IP Right Cessation
- 1997-06-12 KR KR1019980710221A patent/KR20000016625A/ko not_active Application Discontinuation
- 1997-06-12 ES ES97931034T patent/ES2255106T3/es not_active Expired - Lifetime
- 1997-06-12 WO PCT/US1997/009661 patent/WO1997047298A1/en not_active Application Discontinuation
- 1997-06-12 JP JP10501674A patent/JP2000512293A/ja not_active Withdrawn
- 1997-06-12 AU AU34763/97A patent/AU725582B2/en not_active Ceased
- 1997-06-12 CZ CZ984067A patent/CZ406798A3/cs unknown
-
1998
- 1998-12-11 NO NO19985808A patent/NO318193B1/no unknown
Also Published As
Publication number | Publication date |
---|---|
EP0954308B1 (en) | 2006-01-18 |
BR9709727A (pt) | 1999-08-10 |
EP0954308A1 (en) | 1999-11-10 |
AU3476397A (en) | 1998-01-07 |
PL189253B1 (pl) | 2005-07-29 |
IL127524A0 (en) | 1999-10-28 |
DE69735134T2 (de) | 2006-08-17 |
CA2257693A1 (en) | 1997-12-18 |
ATE315933T1 (de) | 2006-02-15 |
NZ333341A (en) | 2000-05-26 |
HUP0003679A3 (en) | 2002-09-30 |
ES2255106T3 (es) | 2006-06-16 |
EA005035B1 (ru) | 2004-10-28 |
DE69735134D1 (de) | 2006-04-06 |
US5723456A (en) | 1998-03-03 |
KR20000016625A (ko) | 2000-03-25 |
EA199900025A1 (ru) | 1999-06-24 |
AU725582B2 (en) | 2000-10-12 |
PL330604A1 (en) | 1999-05-24 |
CZ406798A3 (cs) | 1999-08-11 |
EP0954308A4 (en) | 2001-06-06 |
NO985808D0 (no) | 1998-12-11 |
JP2000512293A (ja) | 2000-09-19 |
YU57398A (sh) | 2000-10-30 |
NO318193B1 (no) | 2005-02-14 |
UA49025C2 (uk) | 2002-09-16 |
WO1997047298A1 (en) | 1997-12-18 |
NO985808L (no) | 1999-02-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0003679A2 (hu) | PKC inhibitorok alkalmazása kardiovaszkuláris megbetegedések kezelésére szolgáló gyógyászati készítmények előállítására | |
NO974595L (no) | Imidazo£1,2-a|pyridin-derivater | |
HUP9901820A2 (hu) | 4-Amino-pirimidin-származékok, ezeket tartalmazó gyógyszerkészítmények, alkalmazásuk és eljárás előállításukra | |
HUP0301120A2 (hu) | Szubsztituált fenilamino-kinazolin-származékok, alkalmazásuk rendellenes sejtnövekedés kezelésére és azokat tartalmazó gyógyszerkészítmények | |
EA200300265A1 (ru) | Производные хиназолина в качестве ингибиторов киназы | |
TR199800759T2 (xx) | Protein Kinaz C �nhibit�r�. | |
ATE400274T1 (de) | Hemmstoffe der akt aktivität | |
HUP0204083A2 (hu) | 2-Amino-nikotin-amid-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és VEGF receptor tirozin kináz inhibitorként való alkalmazásuk | |
BG104996A (en) | Indole derivatives and their use in the treatment of malignant and other diseases caused by pathological cell proliferation | |
MA27561A1 (fr) | Derives d'aminoindazoles et leur utilisation comme inhibiteurs de kinases | |
HUP0401339A2 (hu) | Új 4-anilino-3-kinolinkarboxamidok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
HUP9702040A1 (hu) | Eljárás ateroszklerózis kezelésére | |
DK0711282T3 (da) | Forbindelser som PDE IV og TNF inhibitorer | |
ATE307119T1 (de) | Bicyclische protein-farnesyl-transferase inhibitoren | |
DK0951295T3 (da) | Sammensætninger til anvendelse ved inhibering af alfa-v-beta3-medieret angiogenese | |
GR3025926T3 (en) | Condensed pyrimidine derivatives and their use as angiotensine II antagonists | |
DE60216745D1 (de) | Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion | |
UA35584C2 (uk) | Лікарський засіб для лікування або профілактики ішемії міокарда та спосіб лікування ішемії міокарда у ссавців | |
BG96180A (bg) | Нови антихистаминови средства,производни на бензимидазолите | |
CA2238875A1 (en) | Tri-aryl ethane derivatives as pde iv inhibitors | |
DE69810760D1 (de) | Verbindungen mit kondensierten ringen, verfahren zu ihrer herstellung und ihre anwendung | |
HUP0100489A2 (hu) | Új piperidin-4-szulfonamid-vegyületek, eljárás előállításukra és ezeket tartalmazó gyógyászati készítmények | |
MD382C2 (ro) | Procedeu de obţinere a piperazinilalchil-3(2H)-piridazinonelor sau a sărurilor lor farmaceutice admisibile | |
ATE389655T1 (de) | Pyrimidinderivate | |
ATE287886T1 (de) | Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b) pyridinen als cyclin- abhängige kinase-hemmer |